Xenon Pharmaceuticals(XENE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

XENE Xenon Pharmaceuticals

Market Closed 02-06 16:00:00 EST

41.38

+0.99

+2.45%

盘后41.38

+0.000.00%

16:10 EST

High41.75	Low40.80	Vol611.41K
Open41.09	D1 Closing40.39	Amplitude2.35%
Mkt Cap3.20B	Tradable Cap2.96B	Total Shares77.28M
T/O25.27M	T/O Rate0.85%	Tradable Shares71.60M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"XENE","market":"US","secType":"STK","nameCN":"Xenon Pharmaceuticals","latestPrice":41.38,"timestamp":1770411600000,"preClose":40.39,"halted":0,"volume":611414,"hourTrading":{"tag":"盘后","latestPrice":41.38,"preClose":41.38,"latestTime":"16:10 EST","volume":14736,"amount":609775.68,"timestamp":1770412205027,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.024511017578608615,"floatShares":71595579,"shares":77275005,"eps":-3.886555,"marketStatus":"Market Closed","change":0.99,"latestTime":"02-06 16:00:00 EST","open":41.09,"high":41.745,"low":40.795,"amount":25274656.599928,"amplitude":0.023521,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.886555,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1415163600000,"exchange":"NASDAQ","adjPreClose":40.39,"preHourTrading":{"tag":"盘前","latestPrice":40.99,"preClose":40.39,"latestTime":"08:39 EST","volume":250,"amount":10186.60075,"timestamp":1770385191504,"change":0.6,"changeRate":0.014855,"amplitude":0.021045},"postHourTrading":{"tag":"盘后","latestPrice":41.38,"preClose":41.38,"latestTime":"16:10 EST","volume":14736,"amount":609775.68,"timestamp":1770412205027,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.9021479598386498,"impliedVol":1.3035,"impliedVolPercentile":0.988},"requestUrl":"/m/hq/s/XENE","defaultTab":"news","newsList":[{"id":"2604511801","title":"Xenon (XENE) Receives a Buy from J.P. Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2604511801","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604511801?lang=en_us&edition=fundamental","pubTime":"2026-01-20 20:36","pubTimestamp":1768912591,"startTime":"0","endTime":"0","summary":"J.P. Morgan analyst Tessa Romero maintained a Buy rating on Xenon today and set a price target of $62.00. Romero covers the Healthcare sector, focu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/xenon-xene-receives-a-buy-from-j-p-morgan-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/xenon-xene-receives-a-buy-from-j-p-morgan-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU2023251221.USD","BK4504","LU1989772840.SGD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU2271345857.HKD","LU0098860793.USD","LU1244550577.SGD","LU1162221912.USD","LU0267386448.USD","LU1668664300.SGD","LU0314104364.USD","LU1363072403.SGD","LU1989772923.USD","XBI","LU2089283258.USD","XENE","LU1244550494.USD","LU0234570918.USD","LU1720051108.HKD","LU1732800096.USD","BK4516","LU2089284900.SGD","LU1732799900.SGD","LU2133065610.SGD","LU2028103732.USD","XLV","BK4581","LU0106261372.USD","LU1791710400.SGD","LU0882574139.USD","LU0795875086.SGD","LU0795875169.SGD","BK4534","LABU","LU0006306889.USD","LU0158827781.USD","LU2111349929.HKD","BK4127","LU0225283273.USD","LU0557290698.USD","BK4585","LU0158827948.USD","LU1074936037.SGD","LU1720051017.SGD","LU0528227936.USD","LU0106831901.USD","LU2347655156.SGD","BK4588"],"gpt_icon":0},{"id":"2604919695","title":"Xenon Pharmaceuticals Grants Equity Inducement Options to New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2604919695","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604919695?lang=en_us&edition=fundamental","pubTime":"2026-01-17 05:05","pubTimestamp":1768597522,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals Inc. has granted equity inducement awards to ten new non-officer employees, totaling 42,300 share options. The options have an exercise price of $40.74 per common share, reflecting the closing price on January 15, 2026. These share options vest over four years, with 25% vesting on the one-year anniversary of each employee's start date and the remainder vesting monthly over the following three years. Each option carries a 10-year term and is subject to the terms of the company’s Amended and Restated 2025 Inducement Equity Incentive Plan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on January 16, 2026, an","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDL3rgKZf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","LU2210150020.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014039.USD","NDAQ","BK4139","LU2095319765.USD","BK4585","XENE","BK4588","LU2210149790.SGD","BK4112","SG9999014013.SGD","SG9999014005.SGD","SG9999014021.USD","IE00BKPKM429.USD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2604919616","title":"Press Release: Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2604919616","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604919616?lang=en_us&edition=fundamental","pubTime":"2026-01-17 05:05","pubTimestamp":1768597500,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia and BOSTON, Jan. 16, 2026  -- Xenon Pharmaceuticals Inc. , a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to ten new non-officer employees consisting of an aggregate of 42,300 share options. All of the foregoing share options were approved by the Compensation Committee of the Company's Board of Directors with an effective date of January 15, 2026 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635.Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada, and elsewhere. All other trademarks belong to their respective owner.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0965509101.SGD","LU1116320901.HKD","XENE","LU2404859667.USD","LU0690374615.EUR","LU0158827781.USD","LU1043141123.HKD","GB00B4QBRK32.GBP","BK4227","LU0006306889.USD","LU0048584097.USD","LU1069344957.HKD","LU1046421795.USD","LU1228905540.USD","LU2746668974.SGD","GB00B4LPDJ14.GBP","IE00BKVL7J92.USD","LU2264538146.SGD","LU0690374961.EUR","LU2404859741.USD","LU0426412945.USD","LU1712237335.SGD","LU2326559502.SGD","LU0354030511.USD","LU1804176565.USD","LU1934455194.USD","LU2125154778.USD","LU0787776722.HKD","LU0320765059.SGD","LU0157215616.USD","LU1267930573.SGD","LU0965509010.AUD","BK4585","LU0109392836.USD","LU0708994859.HKD","LU1974910355.USD","LU0310800379.SGD","LU0861579265.USD","LU0868494617.USD","LU1116320737.USD","LU2125154935.USD","LU1823568750.SGD","LU2461242641.AUD","LU2089284900.SGD","LU0079474960.USD","IE00B19Z8W00.USD","NQmain","LU2764262908.HKD","LU1691799644.USD"],"gpt_icon":1},{"id":"2603563759","title":"Xenon Pharmaceuticals: Undervalued ‘Pipeline-in-a-Drug’ Story with Blockbuster Potential Ahead of Key 2026 Readouts","url":"https://stock-news.laohu8.com/highlight/detail?id=2603563759","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603563759?lang=en_us&edition=fundamental","pubTime":"2026-01-14 03:35","pubTimestamp":1768332948,"startTime":"0","endTime":"0","summary":"William Blair analyst Myles Minter has maintained their bullish stance on XENE stock, giving a Buy rating yesterday. Myles Minter has given his Buy...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/xenon-pharmaceuticals-undervalued-pipeline-in-a-drug-story-with-blockbuster-potential-ahead-of-key-2026-readouts-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/xenon-pharmaceuticals-undervalued-pipeline-in-a-drug-story-with-blockbuster-potential-ahead-of-key-2026-readouts-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XENE","BK4139"],"gpt_icon":0},{"id":"2603540616","title":"Xenon Pharmaceuticals: Advancing Late-Stage Epilepsy and Depression Programs and Expanding NaV1.7/Kv7 Pipeline Support Buy Rating and $55 Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2603540616","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603540616?lang=en_us&edition=fundamental","pubTime":"2026-01-13 01:55","pubTimestamp":1768240522,"startTime":"0","endTime":"0","summary":"Xenon, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Serge Belanger from Needham maintained a Buy rating on ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/xenon-pharmaceuticals-advancing-late-stage-epilepsy-and-depression-programs-and-expanding-nav1-7-kv7-pipeline-support-buy-rating-and-55-target-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/xenon-pharmaceuticals-advancing-late-stage-epilepsy-and-depression-programs-and-expanding-nav1-7-kv7-pipeline-support-buy-rating-and-55-target-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XENE","SSI"],"gpt_icon":0},{"id":"2602554295","title":"Analysts Offer Insights on Healthcare Companies: Evolus (EOLS) and Xenon (XENE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2602554295","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602554295?lang=en_us&edition=fundamental","pubTime":"2026-01-11 18:30","pubTimestamp":1768127410,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Evolus (EOLS – Research Report) and Xenon (XENE – ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-evolus-eols-and-xenon-xene-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-evolus-eols-and-xenon-xene-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","BK4581","BK4139","EOLS","LU0029874061.USD","XENE","BK4007","XLV","LU0128526141.USD","BK4588","HCSG","LABU","BK4585","BK4137"],"gpt_icon":0},{"id":"2602756523","title":"Xenon Pharmaceuticals Is Maintained at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2602756523","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602756523?lang=en_us&edition=fundamental","pubTime":"2026-01-09 20:49","pubTimestamp":1767962940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/XENE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 09, 2026 07:49 ET (12:49 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XENE"],"gpt_icon":0},{"id":"2600198096","title":"Xenon Pharmaceuticals CEO Ian Mortimer Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2600198096","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600198096?lang=en_us&edition=fundamental","pubTime":"2026-01-03 07:50","pubTimestamp":1767397818,"startTime":"0","endTime":"0","summary":"Ian Mortimer, President & CEO of Xenon Pharmaceuticals Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenon Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nNDLJvPHv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Xenon Pharmaceuticals CEO Ian Mortimer Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XENE"],"gpt_icon":0},{"id":"2594990292","title":"Biohaven Misses The Mark In Depression Trial, Stock Falls","url":"https://stock-news.laohu8.com/highlight/detail?id=2594990292","media":"Benzinga_recent_news","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594990292?lang=en_us&edition=fundamental","pubTime":"2025-12-26 21:20","pubTimestamp":1766755200,"startTime":"0","endTime":"0","summary":"Biohaven's Phase 2 study with BHV-7000 in MDD did not meet its primary endpoint of reducing depressive symptoms in comparison to placebo.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/26/Medical-Research.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/26/Medical-Research.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49592343/biohaven-misses-the-mark-in-depression-trial-stock-falls","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49592343/biohaven-misses-the-mark-in-depression-trial-stock-falls","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU1093756168.USD","LU1093756325.SGD","XENE","BK4139","BHVN"],"gpt_icon":0},{"id":"2592091186","title":"BUZZ-U.S. STOCKS ON THE MOVE-Spotify, Robinhood Markets, Cannabis stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2592091186","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592091186?lang=en_us&edition=fundamental","pubTime":"2025-12-17 23:40","pubTimestamp":1765986030,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Spotify, Robinhood Markets, Cannabis stocksEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call ne","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nL6N3XN14O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PANW","MCK","XENE","SCCO","KYMR","HL","CNX","FTNT","APOG","CVS","FCF","PSKY","COUR","TXRH","GIS","DHR","NWBI","FISI","FDX","VERU","IMNM","TPL","JBL","NUE","SPOT","WMB","LNG","WAT","COP","ABM","COR","NFE","NEO","AVTR","WSBC","CYTK","HUT","VOR","NEM","FCX","KYTX","CVX","VSCO","ALB","XOM","HOOD"],"gpt_icon":1},{"id":"2592913067","title":"BUZZ-U.S. STOCKS ON THE MOVE-Jabil, Texas Pacific Land, Texas Roadhouse","url":"https://stock-news.laohu8.com/highlight/detail?id=2592913067","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592913067?lang=en_us&edition=fundamental","pubTime":"2025-12-17 22:14","pubTimestamp":1765980847,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Jabil, Texas Pacific Land, Texas RoadhouseEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call new","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nL6N3XN0N8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDE","AIR","APOG","CVS","JBL","TE","TPL","KOD","NEM","IMNM","TXRH","COR","LU2063271972.USD","VOR","LU2750360641.GBP","MCK","HL","HUT","FISI","CYTK","AVTR","USAW.SI","WSBC","PANW","NEO","WAT","FDX","NUE","STLD","UDMY","KYMR","ABM","FCX","COUR","VSCO","GIS","VERU","PSKY","ALB","FCF","NWBI","SCCO","XENE","DHR","FTNT"],"gpt_icon":1},{"id":"2592994926","title":"BUZZ-RBC says biotech sector's rebound has momentum, with intriguing opportunities for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2592994926","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592994926?lang=en_us&edition=fundamental","pubTime":"2025-12-17 19:45","pubTimestamp":1765971925,"startTime":"0","endTime":"0","summary":"BUZZ-RBC says biotech sector's rebound has momentum, with intriguing opportunities for 2026** Brokerage RBC Capital Markets says biotech sector has strongly rebounded since April 2025, helped by good ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nL6N3XN0QE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1201861249.SGD","LU0980610538.SGD","XENE","LU1571399168.USD","BK4135","BK","APGE","BK4588","LU0130102774.USD","LU0130517989.USD","BK4086","APOG","BK4585","LU0477156953.USD","LU0053671581.USD","BK4139","BK4559","KYMR","LU1699723380.USD","LU0648001328.SGD"],"gpt_icon":0},{"id":"2591618986","title":"BRIEF-Eles Says Xenon Increases to 2.95 Eur/Shr Its Offer Price For Eles Bid","url":"https://stock-news.laohu8.com/highlight/detail?id=2591618986","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591618986?lang=en_us&edition=fundamental","pubTime":"2025-12-15 14:47","pubTimestamp":1765781251,"startTime":"0","endTime":"0","summary":"BRIEF-Eles Says Xenon Increases to 2.95 Eur/Shr Its Offer Price For Eles Bid Dec 15  - Eles Semiconductor Equipment S.p.A. ELES.MI on behalf of EBidCo S.r.l.:REPORTED ON SUNDAY XENON INCREASED ITS OFFER PRICE FOR ELES SHARES TO 2.95 EUR/SHRMAXIMUM POTENTIAL EXPENDITURE OF OFFER NOW UP TO EUR 46.63 MLN FOR XENON Further company coverage: ELES.MI  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nL8N3XL05I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XENE"],"gpt_icon":0},{"id":"2591188256","title":"BRIEF-Eles Says Market Regulator Consob Has Approved Xenon Offer Document","url":"https://stock-news.laohu8.com/highlight/detail?id=2591188256","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591188256?lang=en_us&edition=fundamental","pubTime":"2025-12-15 14:35","pubTimestamp":1765780512,"startTime":"0","endTime":"0","summary":"BRIEF-Eles Says Market Regulator Consob Has Approved Xenon Offer DocumentDec 15  - Eles Semiconductor Equipment S.p.A. ELES.MI on behalf of eBidCo S.r.l.:REPORTED ON FRIDAY CONSOB APPROVED XENON OFFER DOCUMENTACCEPTANCE PERIOD TO RUN FROM JAN 5 TO FEB 6, 2026 Further company coverage: ELES.MI   ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nL8N3XL052:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XENE"],"gpt_icon":0},{"id":"2590548065","title":"Xenon Pharmaceuticals Is Maintained at Overweight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2590548065","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590548065?lang=en_us&edition=fundamental","pubTime":"2025-12-12 01:22","pubTimestamp":1765473720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/XENE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 11, 2025 12:22 ET (17:22 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XENE"],"gpt_icon":0},{"id":"2590373298","title":"Xenon Pharmaceuticals CEO Ian Mortimer Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590373298","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590373298?lang=en_us&edition=fundamental","pubTime":"2025-12-10 08:40","pubTimestamp":1765327247,"startTime":"0","endTime":"0","summary":"Ian Mortimer, President & CEO of Xenon Pharmaceuticals Inc., reported a disposal of common shares of Xenon Pharmaceuticals Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenon Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 09, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDLbHcTgN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Xenon Pharmaceuticals CEO Ian Mortimer Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XENE","BK4139"],"gpt_icon":0},{"id":"2589818552","title":"Xenon Pharmaceuticals Reports 48-Month Azetukalner Study Shows 90.9% Seizure Reduction in Epilepsy Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2589818552","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589818552?lang=en_us&edition=fundamental","pubTime":"2025-12-05 22:00","pubTimestamp":1764943230,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals Inc. has announced new data from its ongoing clinical development in epilepsy, including interim 48-month results from the X-TOLE open-label extension  study of azetukalner in patients with focal onset seizures. According to the company, participants treated for 48 months or longer experienced a monthly reduction in seizure frequency of 90.9%, with 38% achieving at least one year of seizure freedom. The new data suggest that long-term use of azetukalner may enable patients to attain and regain extended periods of seizure freedom, including in those with difficult-to-treat disease. These results, along with multiple real-world studies on the burden of depression and anti-seizure medication titration in epilepsy, are being presented at the American Epilepsy Society Annual Meeting , held from December 5-9, 2025, in Atlanta, Georgia. Additionally, new pre-clinical research in Dravet syndrome was presented, indicating potential for improved motor function through Na V ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL9LsGqD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4585","IE00BGHQF748.EUR","XENE","IE00B3QW5Z07.USD","LU0314104364.USD","LU2095319765.USD","BK4588","BK4112","NDAQ","IE00B64PRP62.GBP","BK4139","IE00BKPKM429.USD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2589934858","title":"Xenon Pharmaceuticals Grants Equity Inducements to New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2589934858","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589934858?lang=en_us&edition=fundamental","pubTime":"2025-12-05 06:20","pubTimestamp":1764886807,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals Inc. has granted equity inducement awards to five new non-officer employees, totaling 39,250 share options. The options have an exercise price of $44.61 per common share, reflecting the closing price on December 4, 2025. The options vest over four years, with 25% vesting on the first anniversary of each employee's start date, and the remaining shares vesting in equal monthly installments over the following three years. Each option has a 10-year term.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on December 04, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL96MByH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4585","IE00BGHQF748.EUR","XENE","IE00B3QW5Z07.USD","LU0314104364.USD","LU2095319765.USD","BK4588","BK4112","NDAQ","IE00B64PRP62.GBP","BK4139","IE00BKPKM429.USD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2589385892","title":"Press Release: Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2589385892","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589385892?lang=en_us&edition=fundamental","pubTime":"2025-12-05 06:20","pubTimestamp":1764886800,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia and BOSTON, Dec. 04, 2025  -- Xenon Pharmaceuticals Inc. , a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to five new non-officer employees consisting of an aggregate of 39,250 share options. All of the foregoing share options were approved by the Compensation Committee of the Company's Board of Directors with an effective date of December 4, 2025 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635.Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada, and elsewhere. All other trademarks belong to their respective owner.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1934455863.HKD","LU0472753341.HKD","SG9999014880.SGD","BK4581","V","BK4533","IE00BQXX3D17.EUR","SG9999017495.SGD","LU1803068979.SGD","LU2271345857.HKD","LU0353189680.USD","LU0265550946.USD","LU0476273544.USD","LU1623119135.USD","LU0971096721.USD","LU2746668461.USD","LU0642271901.SGD","LU2242649171.HKD","BK4139","LU0417517546.SGD","LU1917777945.USD","IE00BQXX3C00.GBP","LU1363072403.SGD","LU0079474960.USD","LU1712237335.SGD","IE00BZ1G4Q59.USD","LU0289960550.SGD","LU0868494617.USD","LU0057025933.USD","XENE","SG9999014914.USD","LU0345774391.USD","LU1228905037.USD","LU1633808545.USD","LU0823417737.USD","LU0950375773.USD","LU1035775433.USD","LU1046421795.USD","LU2360032135.SGD","LU2361044949.HKD","LU1852331112.SGD","LU2746668974.SGD","LU0251132253.USD","LU0158827781.USD","NQmain","BK4534","LU2361044865.SGD","LU1974910355.USD","LU1804176565.USD","LU0348723411.USD"],"gpt_icon":0},{"id":"2588769700","title":"Xenon Pharmaceuticals CEO Ian Mortimer Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588769700","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588769700?lang=en_us&edition=fundamental","pubTime":"2025-12-04 09:21","pubTimestamp":1764811274,"startTime":"0","endTime":"0","summary":"Ian Mortimer, President & CEO of Xenon Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenon Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 03, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL46wRny:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Xenon Pharmaceuticals CEO Ian Mortimer Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XENE","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xenon-pharma.com","stockEarnings":[{"period":"1week","weight":0.009},{"period":"1month","weight":-0.0176},{"period":"3month","weight":0.0818},{"period":"6month","weight":0.2378},{"period":"1year","weight":0.0449},{"period":"ytd","weight":-0.0768}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0015},{"period":"3month","weight":0.0293},{"period":"6month","weight":0.0839},{"period":"1year","weight":0.139},{"period":"ytd","weight":0.0128}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":0.008322},{"month":2,"riseRate":0.75,"avgChangeRate":0.072304},{"month":3,"riseRate":0.181818,"avgChangeRate":-0.075368},{"month":4,"riseRate":0.545455,"avgChangeRate":0.022894},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.037416},{"month":6,"riseRate":0.454545,"avgChangeRate":0.032291},{"month":7,"riseRate":0.363636,"avgChangeRate":0.01913},{"month":8,"riseRate":0.727273,"avgChangeRate":0.07504},{"month":9,"riseRate":0.181818,"avgChangeRate":-0.05886},{"month":10,"riseRate":0.454545,"avgChangeRate":0.054946},{"month":11,"riseRate":0.727273,"avgChangeRate":0.050412},{"month":12,"riseRate":0.666667,"avgChangeRate":0.089745}],"exchange":"NASDAQ","name":"Xenon Pharmaceuticals","nameEN":"Xenon Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Xenon Pharmaceuticals(XENE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Xenon Pharmaceuticals(XENE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Xenon Pharmaceuticals,XENE,Xenon Pharmaceuticals股票,Xenon Pharmaceuticals股票老虎,Xenon Pharmaceuticals股票老虎国际,Xenon Pharmaceuticals行情,Xenon Pharmaceuticals股票行情,Xenon Pharmaceuticals股价,Xenon Pharmaceuticals股市,Xenon Pharmaceuticals股票价格,Xenon Pharmaceuticals股票交易,Xenon Pharmaceuticals股票购买,Xenon Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Xenon Pharmaceuticals(XENE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Xenon Pharmaceuticals(XENE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}